AU2008240148B2 - Treatment of down syndrome with benzodiazepine receptor antagonists - Google Patents

Treatment of down syndrome with benzodiazepine receptor antagonists Download PDF

Info

Publication number
AU2008240148B2
AU2008240148B2 AU2008240148A AU2008240148A AU2008240148B2 AU 2008240148 B2 AU2008240148 B2 AU 2008240148B2 AU 2008240148 A AU2008240148 A AU 2008240148A AU 2008240148 A AU2008240148 A AU 2008240148A AU 2008240148 B2 AU2008240148 B2 AU 2008240148B2
Authority
AU
Australia
Prior art keywords
benzodiazepine
pharmaceutical ingredient
active pharmaceutical
composition
flumazenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008240148A
Other languages
English (en)
Other versions
AU2008240148A1 (en
Inventor
Jeffery J. Anderson
Jay D. Kranzler
Srinivas Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of AU2008240148A1 publication Critical patent/AU2008240148A1/en
Application granted granted Critical
Publication of AU2008240148B2 publication Critical patent/AU2008240148B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008240148A 2007-04-11 2008-04-11 Treatment of down syndrome with benzodiazepine receptor antagonists Expired - Fee Related AU2008240148B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91125407P 2007-04-11 2007-04-11
US60/911,254 2007-04-11
PCT/US2008/060133 WO2008128116A1 (en) 2007-04-11 2008-04-11 Treatment of down syndrome with benzodiazepine receptor antagonists

Publications (2)

Publication Number Publication Date
AU2008240148A1 AU2008240148A1 (en) 2008-10-23
AU2008240148B2 true AU2008240148B2 (en) 2012-09-27

Family

ID=39864354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008240148A Expired - Fee Related AU2008240148B2 (en) 2007-04-11 2008-04-11 Treatment of down syndrome with benzodiazepine receptor antagonists

Country Status (5)

Country Link
EP (1) EP2146576A4 (enExample)
JP (1) JP2010523716A (enExample)
AU (1) AU2008240148B2 (enExample)
CA (1) CA2683754A1 (enExample)
WO (1) WO2008128116A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CN112569216B (zh) * 2019-09-30 2022-02-15 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
GB202413915D0 (en) * 2024-09-20 2024-11-06 Fitabeo Therapeutics Ltd treatment of drug use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
ES2278345T3 (es) * 2003-07-25 2007-08-01 Neurogen Corporation Imidazo-pirimidinas y triazolo-pirimidinas: ligandos de receptores de benzodiazepinas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REVESZ et al: Medical and Pediatric Oncology (1993), Vol 21, No 384 *

Also Published As

Publication number Publication date
CA2683754A1 (en) 2008-10-23
AU2008240148A1 (en) 2008-10-23
WO2008128116A1 (en) 2008-10-23
JP2010523716A (ja) 2010-07-15
EP2146576A4 (en) 2013-01-16
EP2146576A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
EP1272218B1 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP2020128384A (ja) 医薬溶液、調製方法及び治療的使用
US20070225316A1 (en) Methods and compositions for treating schizophrenia
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US20100204205A1 (en) Tolerability of mirtazapine and a second active agent by using them in combination
LÉAN et al. Beneficial effects of serotonin precursors in postanoxic action myoclonus
CA2716757A1 (en) Kit, composition, product or medicament for treating cognitive impairment
US20080175903A1 (en) Treatment of anxiety with eszopiclone
US20090275562A1 (en) Tolerability of mirtazapine and a second active by using them in combination
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
KR20140146217A (ko) 파킨슨병을 치료하는 방법
EP2288345A1 (en) Psycho-pharmaceuticals
EA017915B1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
JP2012232978A (ja) ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物
AU2008240148A1 (en) Treatment of down syndrome with benzodiazepine receptor antagonists
ES2224751T3 (es) Uso de (r)-tofisopam opticamente puro para tratar y prevenir transtornos de ansiedad.
US20090270373A1 (en) Treatment of down syndrom with benzodiazepine receptor antagonists
EP3021946A2 (en) Hcn inhibitors affecting ganglion cell function and visual function
TWI457123B (zh) ４－｛３－［順式－六氫環戊并［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺與ｎｍｄａ受體拮抗劑之新結合及包含彼等之醫藥組合物
US8791115B2 (en) Combination of triazine derivatives and insulin sensitisers
AU2006306547A1 (en) Tricyclic compounds useful as oxytocin receptor agonists
RU2277096C2 (ru) Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
WO2013036224A1 (en) Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2013130422A1 (en) Compositions and methods for treating mitochondrial diseases
US20170027949A1 (en) ASSOCIATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee